Alcediag

Alcediag is an innovative diagnostics company pioneering the application of RNA editing biomarkers and AI to address critical unmet needs in mental health. Its core technology, the EDITECH® platform, analyzes epigenetic modifications in blood to develop tests like EDIT-B®, which aims to differentiate unipolar from bipolar depression. As a private company, Alcediag is positioned in the high-growth precision psychiatry market, leveraging a strong IP portfolio and KOL network to advance its commercial and diagnostic pipeline.

EDITECH® platform: An integrated system leveraging RNA editing (A-to-I) epigenetics, next-generation sequencing, and AI/machine learning to discover and validate blood-based diagnostic biomarkers for mental health conditions and drug development applications.

Alcediag is a pioneer in applying RNA editing specifically to psychiatry diagnostics, giving it a niche first-mover advantage. However, it competes in the broader landscape of companies developing blood-based biomarkers for mental health using genomics, proteomics, and metabolomics, including larger diagnostic firms and biotech startups.